================================================================================
SCHEDULE 13D
(RULE 13D-101)
Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and
Amendments Thereto Filed Pursuant to Rule 13d-2(a)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(AMENDMENT NO. 2)
PHAR-MOR, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $.01 PER SHARE
--------------------------------------------------------------------------------
(Title of Class of Securities)
717113-10-3
--------------------------------------------------------------------------------
(CUSIP number)
ROBERT H. STONE
AVATEX CORPORATION
AVATEX FUNDING, INC.
M & A INVESTMENTS, INC.
5910 NORTH CENTRAL EXPRESSWAY, SUITE 1780
DALLAS, TEXAS 75206
(214) 365-7453
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
AUGUST 22, 2000
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[ ].
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including exhibits.
See Rule 13d-7(b) for other parties to whom copies are to be
sent.
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.
<PAGE>
------------------------------------------- ---------------------------------
CUSIP No. 717113-10-3 Page 2 of 6 pages
------------------------------------------- ---------------------------------
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<TABLE>
<CAPTION>
---------------------- ---------------------------------------------------------------------------------------------
<S> <C> <C>
1 Names of Reporting Persons/I.R.S. AVATEX CORPORATION
Identification Nos. of Above Persons (Entities Only:) 25-1425889
---------------------- ---------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group: (a) [X]
(See Instructions) (b) [ ]
---------------------- ---------------------------------------------------------------------------------------------
3 SEC Use Only
---------------------- ---------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions): WC
---------------------- ---------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2 (e) [ ]
---------------------- ---------------------------------------------------------------------------------------------
6 Citizenship or Place of Organization DELAWARE
---------------------- ---------------------------------------------------------------------------------------------
7 Sole Voting Power: 1,224,402
Number of ------------ ---------------------------------------------------------------------------------
Shares 8 Shared Voting Power: 3,824,033
Beneficially ------------ ---------------------------------------------------------------------------------
Owned by 9 Sole Dispositive Power: 1,224,402
Each Reporting ------------ ---------------------------------------------------------------------------------
Person With 10 Shared Dispositive Power: 3,824,033
---------------------- ---------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned
by Each Reporting Person: 5,048,435
---------------------- ---------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions): [ ]
---------------------- ---------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11): 40.9%
---------------------- ---------------------------------------------------------------------------------------------
14 Type of Reporting Person: CO
---------------------- ---------------------------------------------------------------------------------------------
2
<PAGE>
------------------------------------------- ---------------------------------
CUSIP No. 717113-10-3 Page 3 of 6 pages
------------------------------------------- ---------------------------------
---------------------- ---------------------------------------------------------------------------------------------
<S> <C> <C>
1 Names of Reporting Persons/I.R.S. AVATEX FUNDING, INC.
Identification Nos. of Above Persons (Entities Only:) 75-2832486
---------------------- ---------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group: (a) [X]
(See Instructions) (b) [ ]
---------------------- ---------------------------------------------------------------------------------------------
3 SEC Use Only
---------------------- ---------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions): OO
---------------------- ---------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2 (e) [ ]
---------------------- ---------------------------------------------------------------------------------------------
6 Citizenship or Place of Organization DELAWARE
---------------------- ---------------------------------------------------------------------------------------------
7 Sole Voting Power: 0
Number of ------------ ---------------------------------------------------------------------------------
Shares 8 Shared Voting Power: 3,571,533
Beneficially ------------ ---------------------------------------------------------------------------------
Owned by 9 Sole Dispositive Power: 0
Each Reporting ------------ ---------------------------------------------------------------------------------
Person With 10 Shared Dispositive Power: 3,571,533
---------------------- ---------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned
by Each Reporting Person: 3,571,533
---------------------- ---------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions): [ ]
---------------------- ---------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11): 29.0%
---------------------- ---------------------------------------------------------------------------------------------
14 Type of Reporting Person: CO
---------------------- ---------------------------------------------------------------------------------------------
3
<PAGE>
------------------------------------------- ---------------------------------
CUSIP No. 717113-10-3 Page 4 of 6 pages
------------------------------------------- ---------------------------------
---------------------- ---------------------------------------------------------------------------------------------
<S> <C> <C>
1 Names of Reporting Persons/I.R.S. M&A INVESTMENTS, INC.
Identification Nos. of Above Persons (Entities Only:) 75-2521295
---------------------- ---------------------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group: (a) [X]
(See Instructions) (b) [ ]
---------------------- ---------------------------------------------------------------------------------------------
3 SEC Use Only
---------------------- ---------------------------------------------------------------------------------------------
4 Source of Funds (See Instructions): WC
---------------------- ---------------------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2 (e) [ ]
---------------------- ---------------------------------------------------------------------------------------------
6 Citizenship or Place of Organization DELAWARE
---------------------- ---------------------------------------------------------------------------------------------
7 Sole Voting Power: 0
Number of ------------ ---------------------------------------------------------------------------------
Shares 8 Shared Voting Power: 252,500
Beneficially ------------ ---------------------------------------------------------------------------------
Owned by 9 Sole Dispositive Power: 0
Each Reporting ------------ ---------------------------------------------------------------------------------
Person With 10 Shared Dispositive Power: 252,500
---------------------- ---------------------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned
by Each Reporting Person: 252,500
---------------------- ---------------------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions): [ ]
---------------------- ---------------------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11): 2.05%
---------------------- ---------------------------------------------------------------------------------------------
14 Type of Reporting Person: CO
---------------------- ---------------------------------------------------------------------------------------------
</TABLE>
4
<PAGE>
------------------------------------------- ---------------------------------
CUSIP No. 717113-10-3 Page 5 of 6 pages
------------------------------------------- ---------------------------------
This Amendment No. 2 amends and supplements the Statement on Schedule
13D filed with the Securities and Exchange Commission on August 29, 1997, as
amended by Amendment No. 1 thereto filed on August 17, 2000, by Avatex
Corporation, a Delaware corporation ("Avatex"), Avatex Funding, Inc., a Delaware
corporation ("Funding"), and M&A Investments, Inc., a Delaware corporation
("M&A"), with respect to their ownership of common stock, par value $0.01 per
share ("Common Stock"), of Phar-Mor, Inc. ("Phar-Mor"). Avatex, Funding and M&A
are referred to collectively as the "Reporting Persons."
Item 5. Interest in Securities of the Issuer.
------------------------------------
(a) As of the date of this Amendment No. 2, Avatex beneficially owns
5,048,435 shares of Common Stock, which consists of (i) 1,132,500 shares of
Common Stock owned by Avatex, (ii) 91,902 shares underlying warrants to purchase
Common Stock owned by Avatex, (iii) 3,571,533 shares of Common Stock owned by
Funding, and (iv) 252,500 shares of Common Stock owned by M&A. Based upon
12,240,865 shares of Common Stock outstanding as of April 13, 2000, as set forth
in Phar-Mor's Report on Form 10-Q for the fiscal quarter ended April 1, 2000,
plus 91,902 shares beneficially owned by Avatex described in subsection (a) of
this Item 5 that would be issued upon the exercise of warrants held by Avatex,
Avatex beneficially owns approximately 40.9% of Phar-Mor's outstanding Common
Stock, Funding beneficially owns approximately 29.0% of Phar-Mor's outstanding
Common Stock and M&A beneficially owns approximately 2.05% of Phar-Mor's
outstanding Common Stock.
(b) Avatex has the sole power to vote or to direct the vote of, and to
dispose or to direct the disposition of, 1,132,500 shares of Common Stock owned
by Avatex and 91,902 shares underlying warrants to purchase Common Stock owned
by Avatex. Avatex and Funding have shared power to vote or to direct the vote
of, and to dispose or to direct the disposition of, 3,571,533 shares of Common
Stock owned by Funding. Avatex and M&A have shared power to vote or to direct
the vote of, and to dispose or to direct the disposition of, 252,500 shares of
Common Stock owned by M&A.
(c) Since the filing of Amendment No. 1 to Schedule 13D on
August 17, 2000, M&A purchased a total of 122,500 shares of Common Stock on the
Nasdaq National Market as follows:
Trade Date No. of Shares Price per Share
---------- ------------- ---------------
08/17/00 50,000 $ 1.3750
08/18/00 62,500 1.3000
08/21/00 5,000 1.2500
08/22/00 5,000 1.2500
Total: 122,500
5
<PAGE>
------------------------------------------- ---------------------------------
CUSIP No. 717113-10-3 Page 6 of 6 pages
------------------------------------------- ---------------------------------
The Reporting Persons have not effected any other transactions
involving Common Stock since August 17, 2000.
Signatures
After reasonable inquiry and to the best of the undersigned's knowledge
and belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: August 23, 2000.
Avatex Corporation
Avatex Funding, Inc.
M & A Investments, Inc.
By: /s/ Abbey J. Butler
----------------------------------
Abbey J. Butler
Co-Chief Executive Officer
6
